Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 16, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs on August 11, 2006, at a price of $55.04 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rules 3.1.4R(1)(b) regarding the transaction of Dr. M M Slaoui.
Investor Verification Points
- Verify the specific impact of the US Retirement Savings Plan re-valuation on executive compensation or holdings.
- Confirm the transaction date of August 11, 2006, and the share price of $55.04 per ADR.
- Note that this filing does not contain quarterly or annual financial results.